GCM
RNAM

Graham Capital Management’s Avidity Biosciences RNAM Stock Holding History

Graham Capital Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-11,993
Closed -$76.5K – 1282
2023
Q3 		$76.5K Sell
11,993
-7,084
-37% -$61K ﹤0.01% 944
2023
Q2 		$212K Buy
+19,077
New +$239K 0.01% 800
2022
Q4 		– Sell
-35,640
Closed -$582K – 1298
2022
Q3 		$582K Buy
+35,640
New +$682K 0.02% 699

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Graham Capital Management's RNAM Position: Q4 2023 in Review

Graham Capital Management sold out of Avidity Biosciences (RNAM) in Q4 2023, closing a stake of 11,993 shares — an estimated $76.5K sold.

Graham Capital Management first reported a position in RNAM in Q3 2022 and held it in 3 quarters. The position peaked at $582K in Q3 2022. 144 funds tracked by Wall St. Rank hold RNAM as of Q4 2023.

  • Graham Capital Management reported no remaining Avidity Biosciences position as of Q4 2023 after selling out during the quarter.
  • Graham Capital Management sold 11,993 Avidity Biosciences shares in Q4 2023, an estimated $76.5K.
  • Graham Capital Management first reported a position in Avidity Biosciences in Q3 2022 and held it in 3 quarters.
  • Graham Capital Management's Avidity Biosciences position peaked at $582K in Q3 2022.
  • 144 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2023.

Based on Graham Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.